1. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
- Author
-
Risbridger G.P., Clark A.K., Porter L.H., Toivanen R., Bakshi A., Lister N.L., Pook D., Pezaro C.J., Sandhu S., Keerthikumar S., Quezada Urban R., Papargiris M., Kraska J., Madsen H.B., Wang H., Richards M.G., Niranjan B., O'Dea S., Teng L., Wheelahan W., Li Z., Choo N., Ouyang J.F., Thorne H., Devereux L., Hicks R.J., Sengupta S., Harewood L., Iddawala M., Azad A.A., Goad J., Grummet J., Kourambas J., Kwan E.M., Moon D., Murphy D.G., Pedersen J., Clouston D., Norden S., Ryan A., Furic L., Goode D.L., Frydenberg M., Lawrence M.G., Taylor R.A., Risbridger G.P., Clark A.K., Porter L.H., Toivanen R., Bakshi A., Lister N.L., Pook D., Pezaro C.J., Sandhu S., Keerthikumar S., Quezada Urban R., Papargiris M., Kraska J., Madsen H.B., Wang H., Richards M.G., Niranjan B., O'Dea S., Teng L., Wheelahan W., Li Z., Choo N., Ouyang J.F., Thorne H., Devereux L., Hicks R.J., Sengupta S., Harewood L., Iddawala M., Azad A.A., Goad J., Grummet J., Kourambas J., Kwan E.M., Moon D., Murphy D.G., Pedersen J., Clouston D., Norden S., Ryan A., Furic L., Goode D.L., Frydenberg M., Lawrence M.G., and Taylor R.A.
- Abstract
Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-derived xenografts (PDXs) of prostate cancer for rapid and systematic evaluation of candidate therapies. The PDX collection comprises 59 tumors collected from 30 patients between 2012-2020, coinciding with availability of abiraterone and enzalutamide. The PDXs represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naive primary tumors to castration-resistant metastases. Inter- and intra-tumor heterogeneity in adenocarcinoma and neuroendocrine phenotypes is evident from bulk and single-cell RNA sequencing data. Organoids can be cultured from PDXs, providing further capabilities for preclinical studies. Using a 1 x 1 x 1 design, we rapidly identify tumors with exceptional responses to combination treatments. To govern the distribution of PDXs, we formed the Melbourne Urological Research Alliance (MURAL). This PDX collection is a substantial resource, expanding the capacity to test and prioritize effective treatments for prospective clinical trials in prostate cancer.Copyright © 2021, The Author(s).
- Published
- 2021